Elite Journal of Haematology. Volume 2 Issue 7(2024), Pp. 1-12
https://epjournals.com/journals/EJH

The Dual Nature of Free Radicals: Friend and Foe in Sickle Cell Anemia

Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

emmanuelobeagu@yahoo.com

Abstract

Free radicals, including reactive oxygen species (ROS) and reactive nitrogen species (RNS), play a dual role in Sickle Cell Anemia (SCA), acting as both contributors to disease pathology and as essential modulators of physiological processes. In SCA, the mutation in the β-globin gene leads to the production of hemoglobin S (HbS), which induces oxidative stress through ROS and RNS generation. This oxidative stress contributes to key pathological features of the disease, including hemolysis, inflammation, and vaso-occlusive crises. However, recent research has also highlighted that free radicals can have beneficial roles, such as participating in redox signaling pathways and enhancing immune responses. This review explores the complex dual nature of free radicals in SCA, focusing on their detrimental effects, including the promotion of oxidative damage to red blood cells and the exacerbation of vascular and inflammatory responses. Simultaneously, we examine their beneficial roles, such as their involvement in cellular signaling mechanisms and their potential to activate adaptive stress responses that may offer therapeutic opportunities. Emerging therapeutic strategies are also discussed, aiming to strike a balance between mitigating the harmful effects of free radicals while harnessing their beneficial properties. This includes the development of targeted antioxidants, gene therapies, and pharmacological modulators designed to manage oxidative stress without compromising the essential physiological functions of free radicals.

Keywords: *Sickle Cell Anemia, Free Radicals, Reactive Oxygen Species, Oxidative Stress, Inflammation, Antioxidants, Cellular Signaling*

Introduction

Sickle Cell Anemia (SCA) is a genetic blood disorder caused by a mutation in the β-globin gene, which leads to the production of hemoglobin S (HbS). This mutation causes red blood cells (RBCs) to adopt an abnormal sickle shape under deoxygenated conditions. The sickled cells are less flexible and more prone to clumping, which leads to a range of clinical manifestations including vaso-occlusive crises, chronic hemolysis, and multi-organ damage. Central to these pathophysiological processes is the role of free radicals—reactive oxygen species (ROS) and

Citation: Obeagu EI. The Dual Nature of Free Radicals: Friend and Foe in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 1-12

reactive nitrogen species (RNS). Traditionally viewed as harmful, recent research reveals a more nuanced perspective where these free radicals also play beneficial roles.[1-5] The SCA mutation involves a single nucleotide substitution in the β-globin gene, where adenine is replaced by thymine, resulting in the amino acid substitution of valine for glutamic acid at position 6 of the β-globin chain. This mutation causes HbS to polymerize under low oxygen conditions, leading to the sickling of RBCs. The sickling process triggers a cascade of events including increased oxidative stress and inflammation, which significantly contribute to the disease's severity. However, this same sickling phenomenon has led researchers to explore both the damaging and potentially adaptive roles of free radicals generated during these processes.[6-10] Free radicals are highly reactive molecules with unpaired electrons that can damage cellular macromolecules. ROS include superoxide anion ($O_2^{\bullet-}$), hydrogen peroxide (H_2O_2), and hydroxyl radical ($^{\bullet}OH$), while RNS include nitric oxide (NO) and peroxynitrite ($ONOO^-$). In SCA, ROS and RNS are generated due to the pathological effects of HbS polymerization and subsequent RBC sickling. These radicals contribute to oxidative stress, which is central to many of the disease's symptoms. However, free radicals are also involved in normal cellular signaling and immune responses, indicating a complex interplay between their harmful and beneficial effects.[11-12]

In SCA, free radicals exacerbate the disease through several mechanisms. ROS leads to oxidative damage of RBC membranes, contributing to hemolysis and the release of free heme, which further generates ROS. This oxidative damage extends to endothelial cells, contributing to vaso-occlusive events and inflammation. Additionally, RNS interact with ROS to form peroxynitrite, a potent oxidant that exacerbates endothelial dysfunction and promotes vaso-occlusive crises. Despite their harmful effects, free radicals also play crucial roles in cellular physiology. ROS and RNS are involved in redox signaling, which regulates various physiological processes including cell proliferation, apoptosis, and immune responses. In SCA, these beneficial roles can include the activation of stress responses that help cells adapt to oxidative damage. This dual role of free radicals in SCA highlights the need for therapeutic strategies that do not merely neutralize these molecules but instead modulate their effects to achieve a balance between harm and benefit.[13-20] Redox signaling is a process where ROS and RNS function as signaling molecules that regulate cellular functions and stress responses. In SCA, redox signaling pathways influence RBC production, the inflammatory response, and the regulation of cell survival. While excessive ROS production leads to damage, moderate levels of ROS can activate adaptive responses that might protect cells from further damage. This aspect of redox biology opens up new avenues for therapies that aim to harness the beneficial effects of free radicals while controlling their harmful impacts.[21-22]

Antioxidants are molecules that neutralize ROS and RNS, protecting cells from oxidative damage. In SCA, both endogenous antioxidants (like glutathione and superoxide dismutase) and exogenous antioxidants (such as Vitamin E and N-acetylcysteine) are used to manage oxidative stress. These antioxidants can reduce the oxidative damage caused by free radicals, thereby alleviating symptoms of SCA. However, the challenge is to develop therapies that selectively target harmful

oxidative processes without disrupting beneficial free radical functions. Recent advancements have led to the development of targeted antioxidants designed to specifically address the sources of oxidative stress in SCA. Compounds such as MitoQ, which targets mitochondrial ROS, and other mitochondrial-targeted antioxidants offer new therapeutic possibilities. These targeted therapies aim to reduce oxidative damage in a more precise manner, potentially offering a way to manage the disease while preserving beneficial redox signaling mechanisms.[23-27] Gene therapy and gene editing technologies offer potential solutions for the dual nature of free radicals in SCA. Techniques like CRISPR/Cas9 and LentiGlobin gene therapy aim to correct the β-globin mutation or introduce beneficial genetic modifications. These approaches not only aim to correct the root cause of the disease but also have the potential to modulate the redox environment in a way that could balance the harmful and beneficial effects of free radicals. Pharmacological modulators are another promising area of research. These include drugs that can selectively modulate redox balance, reduce oxidative damage, or enhance adaptive stress responses. Examples include hydroxyurea, which acts as an antioxidant and anti-inflammatory agent, and emerging compounds designed to selectively target oxidative stress pathways. Such therapies aim to manage SCA by addressing both the pathological and protective roles of free radicals.[28-32]

The Role of Free Radicals in Sickle Cell Anemia

Free radicals, particularly reactive oxygen species (ROS) and reactive nitrogen species (RNS), play multifaceted roles in Sickle Cell Anemia (SCA), significantly influencing the disease's pathology. These reactive molecules are central to the disease mechanisms that lead to the characteristic symptoms of SCA, including oxidative stress, hemolysis, and vaso-occlusive crises. This section delves into the dual roles of free radicals in SCA, exploring both their damaging effects and their physiological functions. In SCA, the sickling of red blood cells (RBCs) due to the mutation in the β-globin gene leads to various sources of ROS and RNS. The primary source of ROS in SCA is the polymerization of hemoglobin S (HbS). When HbS molecules aggregate under low oxygen conditions, they form long, rigid polymers that distort the shape of RBCs.[33-37] The sickling process leads to the oxidation of hemoglobin, resulting in the formation of methemoglobin and free heme. Free heme can catalyze the generation of ROS, including superoxide anions ($O_2^{\bullet-}$) and hydroxyl radicals (•OH), through Fenton and Haber-Weiss reactions. The chronic hemolysis of sickled RBCs releases heme and iron into the bloodstream, where they can further react to produce ROS. Hemolysis also triggers the activation of inflammatory pathways that produce additional free radicals. SCA is associated with a chronic inflammatory state characterized by the activation of leukocytes and the release of pro-inflammatory cytokines. This inflammation stimulates the production of ROS and RNS, exacerbating oxidative stress and tissue damage.[38-41]

ROS attack polyunsaturated fatty acids in the RBC membrane, leading to lipid peroxidation. This damage compromises membrane integrity, contributing to hemolysis and the release of cell

contents into the bloodstream. Oxidation of RBC membrane proteins, such as spectrin and ankyrin, disrupts the cytoskeletal structure of RBCs, further destabilizing the cell membrane and promoting hemolysis. ROS can induce DNA damage, which may lead to mutations and genomic instability in RBC precursors, potentially affecting erythropoiesis and contributing to disease progression. ROS and RNS damage endothelial cells lining blood vessels, leading to increased adhesion of sickled RBCs to the endothelium and exacerbation of vaso-occlusive events. The oxidative damage to RBCs and plasma proteins can increase blood viscosity, which contributes to the obstruction of blood flow in small vessels.[42-26]

Low levels of ROS can activate cellular stress responses that promote adaptation and resistance to further oxidative damage. This includes the activation of antioxidant defenses and repair mechanisms that mitigate the harmful effects of excessive ROS. ROS and RNS are involved in the innate immune response. They help to neutralize pathogens and modulate immune cell function, which is crucial for managing infections in SCA patients who are at higher risk for infections. In SCA, mild oxidative stress can trigger adaptive responses that enhance the resilience of cells to higher levels of oxidative damage. This hormetic effect can contribute to cellular survival and function despite the ongoing stress from ROS and RNS.[47-50] This drug reduces oxidative stress by increasing fetal hemoglobin (HbF) levels and exhibiting direct antioxidant properties. N-Acetylcysteine (NAC) replenishes glutathione levels and serves as a direct antioxidant, mitigating oxidative damage in SCA patients. Compounds like MitoQ target mitochondrial ROS specifically, aiming to reduce oxidative damage while preserving beneficial signaling functions. Innovations such as CRISPR/Cas9 aim to correct the β-globin mutation and modulate the oxidative stress response to improve patient outcomes.[51-52]

Beneficial Roles of Free Radicals

Free radicals, including reactive oxygen species (ROS) and reactive nitrogen species (RNS), are often associated with cellular damage and disease progression. However, in the context of Sickle Cell Anemia (SCA), these molecules also have essential physiological roles that can be leveraged for therapeutic benefits. Understanding the beneficial roles of free radicals in SCA provides a more balanced perspective on their functions and highlights potential avenues for novel treatment strategies. Free radicals play a crucial role in redox signaling, which is a fundamental process for cellular adaptation and stress responses. ROS activate transcription factors like Nuclear Factor Erythroid 2–Related Factor 2 (Nrf2) and Nuclear Factor kappa B (NF-κB). Nrf2 activation leads to the expression of antioxidant and cytoprotective genes, which help cells cope with increased oxidative stress. NF-κB activation initiates inflammatory responses that are essential for immune defense and tissue repair. Redox signaling pathways induced by ROS leads to increased expression of antioxidants such as glutathione peroxidase, catalase, and superoxide dismutase. These antioxidants mitigate further oxidative damage and maintain redox homeostasis, which is crucial for cellular health.[53-57]

Citation: Obeagu EI. The Dual Nature of Free Radicals: Friend and Foe in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 1-12

Free radicals are integral to the immune system's ability to combat infections and modulate inflammation. ROS produced by phagocytes during the respiratory burst are used to kill pathogens. This oxidative burst is a crucial defense mechanism against bacterial and viral infections, which SCA patients are particularly susceptible to. While excessive inflammation can be damaging, controlled ROS and RNS production helps to regulate inflammatory responses. This regulation ensures that inflammation is maintained at a level that can promote healing and prevent excessive tissue damage. ROS and RNS serve as signaling molecules that regulate the activation, differentiation, and function of immune cells. For instance, ROS influence T-cell activation and B-cell antibody production, which are essential for the adaptive immune response. Hormesis is a phenomenon where low doses of a stressor induce beneficial effects by activating adaptive responses. In SCA, mild oxidative stress can stimulate hormetic responses that enhance cellular resilience: Mild oxidative stress caused by ROS can trigger adaptive stress responses. These include the upregulation of heat shock proteins and repair enzymes that protect cells from more severe oxidative damage. Hormetic effects of free radicals can enhance cellular functions such as protein folding, DNA repair, and cell survival. This response can be beneficial in managing the chronic oxidative stress associated with SCA.[58-62]

ROS can stimulate erythropoietin production and erythroid progenitor cell proliferation. This effect helps to compensate for the loss of RBCs due to hemolysis and supports increased RBC production. ROS and RNS are involved in signaling pathways that influence the production of fetal hemoglobin (HbF). Elevated HbF levels reduce sickling and improve clinical outcomes in SCA patients. ROS are involved in endothelial cell signaling that regulates vascular tone and blood flow. While excessive ROS can cause endothelial dysfunction, controlled ROS signaling maintains vascular health and regulates blood pressure. RNS, particularly nitric oxide (NO), are critical for vasodilation and maintaining vascular tone. In SCA, NO produced from the reaction of ROS with RNS can modulate vascular responses and reduce the severity of vaso-occlusive crises.[64-65] Compounds that specifically modulate ROS and RNS levels, such as MitoQ, aim to reduce oxidative damage while preserving beneficial signaling functions. Gene therapies designed to correct the β-globin mutation or enhance the expression of antioxidant enzymes are being explored to balance the dual roles of free radicals in SCA.[66]

Therapeutic Strategies Targeting the Dual Nature of Free Radicals

In Sickle Cell Anemia (SCA), free radicals play a complex role as both agents of disease pathology and participants in beneficial physiological processes. Effective therapeutic strategies must therefore address the dual nature of free radicals, aiming to mitigate their harmful effects while harnessing their beneficial roles. This section explores current and emerging therapeutic approaches designed to balance these Antioxidant therapies are well-established for reducing oxidative stress and its detrimental effects in SCA. These therapies focus on neutralizing harmful ROS and RNS while attempting to preserve or enhance the beneficial aspects of oxidative stress. Hydroxyurea is a cornerstone of SCA treatment. It increases fetal hemoglobin (HbF) levels, which

reduces red blood cell sickling. Additionally, hydroxyurea has direct antioxidant properties that decrease ROS production, thereby reducing oxidative stress and inflammation in SCA patients. N-Acetylcysteine (NAC) is a precursor of glutathione, a major intracellular antioxidant. It helps replenish glutathione levels and directly scavenges ROS. NAC also modulates redox signaling pathways to protect cells from oxidative damage.[67-71] Mitochondrial Antioxidants **(**MitoQ) is a mitochondria-targeted antioxidant that specifically reduces mitochondrial ROS. Given that mitochondria are central to both oxidative stress and cellular energy production, MitoQ aims to reduce oxidative damage while supporting mitochondrial function. New compounds, such as Tempol and Apocynin, have shown potential in reducing oxidative stress in SCA. Tempol is a radical scavenger that reduces ROS levels, while Apocynin inhibits NADPH oxidase activity, a major source of ROS.[72]

CRISPR/Cas9 technology can be used to correct the β-globin gene mutation responsible for SCA. By editing the gene to produce normal hemoglobin or increase HbF levels, this approach targets the root cause of the disease and reduces the secondary effects of oxidative stress. Techniques such as lentiviral vector-mediated gene transfer aim to introduce therapeutic genes that produce beneficial proteins. For instance, adding genes for antioxidant enzymes like superoxide dismutase or catalase can help counteract oxidative damage in SCA. Drugs like Pentoxifylline reduce inflammation and oxidative stress. Pentoxifylline improves blood flow, reduces sickling, and has antioxidant properties that decrease ROS levels. Nitric oxide donors, such as L-arginine, can enhance NO levels, which is beneficial for vascular health in SCA. By promoting vasodilation and reducing vaso-occlusive events, these agents leverage the positive effects of RNS. Combining antioxidant therapies with gene editing or addition approaches could provide synergistic effects. For example, using Hydroxyurea in conjunction with CRISPR/Cas9 gene therapy might maximize therapeutic benefits by both reducing oxidative stress and correcting genetic mutations. Combining pharmacological agents that modulate redox signaling with lifestyle interventions such as diet and exercise could optimize treatment outcomes. For instance, a combination of NO donors with dietary antioxidants may offer enhanced vascular and cellular benefits.[73]

Conclusion

Free radicals are central to the pathophysiology of Sickle Cell Anemia (SCA), with their dual nature presenting both challenges and opportunities for therapeutic intervention. On one hand, oxidative stress driven by reactive oxygen species (ROS) and reactive nitrogen species (RNS) exacerbates the disease by causing hemolysis, promoting inflammation, and triggering vaso-occlusive crises. On the other hand, free radicals play essential physiological roles in redox signaling, immune responses, and cellular adaptation that can be harnessed for therapeutic benefit. Traditional antioxidant therapies such as Hydroxyurea and N-Acetylcysteine (NAC) aim to reduce oxidative stress and its damaging effects. Hydroxyurea's ability to increase fetal hemoglobin (HbF) and its antioxidant properties have made it a cornerstone of SCA treatment. NAC, as a precursor to glutathione, helps to restore antioxidant defenses and reduce oxidative damage.

Citation: Obeagu EI. The Dual Nature of Free Radicals: Friend and Foe in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 1-12

References

1. Ata F, Rahhal A, Malkawi L, Iqbal P, Khamees I, Alhiyari M, Yousaf Z, Qasim H, Alshurafa A, Sardar S, Javed S. Genotypic and phenotypic composition of sickle cell disease in the Arab population-a systematic review. Pharmacogenomics and Personalized Medicine. 2023:133-144.
2. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
3. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
4. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
5. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
6. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
7. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-158.
8. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.
9. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
10. Nur E, Biemond BJ, Otten HM, Brandjes DP, Schnog JJ, CURAMA Study Group. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. American journal of hematology. 2011;86(6):484-849.
11. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-2487.
12. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
13. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
14. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
15. Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.
16. Wang Q, Zennadi R. The role of RBC oxidative stress in sickle cell disease: from the molecular basis to pathologic implications. Antioxidants. 2021;10(10):1608.

Citation: Obeagu EI. The Dual Nature of Free Radicals: Friend and Foe in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 1-12

17. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
18. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023;6(2):10-13.
19. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
20. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(1):218-234.
21. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
22. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
23. Ifeanyi OE, Stella EI, Favour AA. Antioxidants in the Management of Sickle Cell Anaemia. Int J Hematol Blood Disord, 2018; 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018.
24. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
25. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-265.
26. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
27. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
28. Hernansanz-Agustín P, Enríquez JA. Generation of reactive oxygen species by mitochondria. Antioxidants. 2021;10(3):415.
29. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-13.
30. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
31. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.

Citation: Obeagu EI. The Dual Nature of Free Radicals: Friend and Foe in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 1-12

32. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
33. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
34. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
35. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
36. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
37. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.
38. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
39. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024;103(6):e37127.
40. Orrico F, Laurance S, Lopez AC, Lefevre SD, Thomson L, Möller MN, Ostuni MA. Oxidative stress in healthy and pathological red blood cells. Biomolecules. 2023;13(8):1262.
41. Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.
42. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
43. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
44. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024 Jan 12;103(2):e36898.
45. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
46. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
47. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).

Citation: Obeagu EI. The Dual Nature of Free Radicals: Friend and Foe in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 1-12

48. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
49. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
50. Obeagu EI, Obeagu GU. The Role of Parents: Strengthening Adolescent Education for Sickle Cell Disease Prevention. Elite Journal of Public Health. 2024;2(1):15-21.
51. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:67-80.
52. Obeagu EI, Obeagu GU. Overcoming Hurdles: Anemia Management in Malaria-Affected Childhood. Elite Journal of Laboratory Medicine. 2024;2(1):59-69.
53. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine (Baltimore). 2024 ;103(2):e36898. doi: 10.1097/MD.0000000000036898. PMID: 38215146; PMCID: PMC10783340.
54. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anaemia survival rates. Ann Med Surg (Lond). 2024;86(3):1570-1574. doi: 10.1097/MS9.0000000000001763. PMID: 38463100; PMCID: PMC10923353.
55. Obeagu EI, Obeagu GU. Malnutrition in sickle cell anemia: Prevalence, impact, and interventions: A Review. Medicine (Baltimore). 2024;103(20):e38164. doi: 10.1097/MD.0000000000038164. PMID: 38758879; PMCID: PMC11098235.
56. Obeagu EI, Obeagu GU. Management of diabetes mellitus patients with sickle cell anemia: Challenges and therapeutic approaches. Medicine (Baltimore). 2024;103(17):e37941. doi: 10.1097/MD.0000000000037941. PMID: 38669382; PMCID: PMC11049766.
57. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine (Baltimore). 2023;102(48):e36462. doi: 10.1097/MD.0000000000036462. PMID: 38050205; PMCID: PMC10695528.
58. Dilli PP, Obeagu E, Tamale A, Ajugwo A, Pius T, Makeri D. Update on the practice of premarital screening for sickle cell traits in Africa: a systematic review and meta-analysis. BMC Public Health. 2024 May 31;24(1):1467. doi: 10.1186/s12889-024-19001-y. PMID: 38822327; PMCID: PMC11143629.
59. Obeagu EI, Obeagu GU. Managing gastrointestinal challenges: Diarrhea in sickle cell anemia. Medicine (Baltimore). 2024;103(18):e38075. doi: 10.1097/MD.0000000000038075. PMID: 38701274; PMCID: PMC11062666.
60. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine (Baltimore). 2024;103(6):e37127. doi: 10.1097/MD.0000000000037127. PMID: 38335412; PMCID: PMC10860944.
61. Obeagu EI. Eosinophilic dialogues: A molecular exploration of sickle cell anemia severity. Annals of Medicine and Surgery. 2024:10-97.

Citation: Obeagu EI. The Dual Nature of Free Radicals: Friend and Foe in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 1-12

62. Pisoschi AM, Pop A, Iordache F, Stanca L, Predoi G, Serban AI. Oxidative stress mitigation by antioxidants-an overview on their chemistry and influences on health status. European Journal of Medicinal Chemistry. 2021; 209:112891.
63. Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacology & therapeutics. 2014;141(2):150-159.
64. Park SH, Bao G. CRISPR/Cas9 gene editing for curing sickle cell disease. Transfusion and Apheresis Science. 2021;60(1):103060.
65. Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatric blood & cancer. 2012;59(2):365-371.
66. Sadaf A, Quinn CT. L-glutamine for sickle cell disease: Knight or pawn? Experimental Biology and Medicine. 2020;245(2):146-54.
67. Chou ST, Fasano RM. Management of patients with sickle cell disease using transfusion therapy: guidelines and complications. Hematology/Oncology Clinics. 2016;30(3):591-608.
68. Leonard A, Tisdale J, Abraham A. Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy? British journal of haematology. 2020;189(3):408-423.
69. Silva DG, Junior EB, De Almeida EA, Bonini-Domingos CR. Oxidative stress in sickle cell disease: an overview of erythrocyte redox metabolism and current antioxidant therapeutic strategies. Free Radical Biology and Medicine. 2013; 65:1101-1109.
70. Ahmed SG, Ibrahim UA. A compendium of pathophysiologic basis of etiologic risk factors for painful vaso-occlusive crisis in sickle cell disease. Nigerian Journal of Basic and Clinical Sciences. 2017;14(2):57-77.
71. Lakkakula BV, Sahoo R, Verma H, Lakkakula S. Pain management issues as part of the comprehensive care of patients with sickle cell disease. Pain Management Nursing. 2018;19(6):558-572.
72. Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. Journal of Hematology & Oncology. 2022;15(1):20.
73. Hoban MD, Orkin SH, Bauer DE. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood, The Journal of the American Society of Hematology. 2016;127(7):839-848.

Citation: Obeagu EI. The Dual Nature of Free Radicals: Friend and Foe in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 1-12